CBUS

SEC source: 0001127602-19-011543 · form4.xml · nonDerivative · entry 2

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vested 33.3% on October 10, 2018, with 33.3% vesting on October 10, 2019, and 33.4% vesting on October 10, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.19 to $16.99, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

SEC source: 0001127602-19-011547 · form4.xml · nonDerivative · entry 1

Blome James · CIK 0001753563 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,882

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on September 17, 2018 and vested 25% on October 1, 2018, with 15% vesting on October 1, 2019, and the remainder vesting quarterly (commencing with the fourth fiscal quarter of 2019) in equal installments over 36 months.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $17.26, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001127602-19-011543 · form4.xml · nonDerivative · entry 1

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vested 33.3% on October 10, 2018, with 33.3% vesting on October 10, 2019, and 33.4% vesting on October 10, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.665 to $17.79, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001127602-19-008461 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 208,361

Underlying: Common Stock · 3,977 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014 and vested 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vested quarterly in equal installments thereafter, 15% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering.

SEC source: 0001127602-19-008461 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-008461 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,959

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-005213 · form4.xml · derivative · entry 1

Koschak William · CIK 0001763989 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2029-02-08

F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock was granted on February 8, 2019 and vests 15% on the first anniversary of the date of grant and 10% on the second anniversary of the date of grant, with the remainder vesting quarterly in equal installments over the following 45 months.

SEC source: 0001127602-19-003835 · form4.xml · derivative · entry 6

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,083

Underlying: Common Stock · 4,087 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014 and vested 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vested quarterly in equal installments thereafter, 15% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering.

SEC source: 0001127602-19-003835 · form4.xml · nonDerivative · entry 4

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-003835 · form4.xml · nonDerivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,069

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-003835 · form4.xml · derivative · entry 5

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,170

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014 and vested 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vested quarterly in equal installments thereafter, 15% of which vested immediately on July 25, 2017 when Calyxt, Inc. underwent its initial public offering.

SEC source: 0001127602-19-003835 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-003835 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-001635 · form4.xml · nonDerivative · entry 1

Dumont Philippe · CIK 0001712186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,060

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.

F2 · balance_after: Includes 16,660 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 2,940 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-001258 · form4.xml · nonDerivative · entry 1

Sahoo Manoj · CIK 0001712226 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,669

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.63, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 58,800 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017, remain unvested and will vest quarterly in equal installments over the following 36 months.

SEC source: 0001127602-18-036959 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,253

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-036959 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-036959 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-032714 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,336

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-032714 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-032714 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-030029 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,419

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-030029 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.72 to $14.11, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-030029 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-029918 · form4.xml · derivative · entry 2

NEUGENT CHRISTOPHER J · CIK 0001657549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,400

Underlying: Common Stock · 29,400 shares

Expires 2028-10-08

F2 · derivative.exercise_date: The Stock Option was granted on October 8, 2018 and vests 15% on October 8, 2019 and 15% on October 8, 2020, with the remainder vesting quarterly (commencing with the first fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-18-029918 · form4.xml · nonDerivative · entry 1

NEUGENT CHRISTOPHER J · CIK 0001657549 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,600

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on October 8, 2018 and vests 15% on October 8, 2019 and 15% on October 8, 2020, with the remainder vesting quarterly (commencing with the first fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-18-029916 · form4.xml · derivative · entry 2

Jonathan Fassberg · CIK 0001750985 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,400

Underlying: Common Stock · 29,400 shares

Expires 2028-10-08

F2 · derivative.exercise_date: The Stock Option was granted on October 8, 2018 and vests 15% on October 8, 2019 and 15% on October 8, 2020, with the remainder vesting quarterly (commencing with the first fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-18-029916 · form4.xml · nonDerivative · entry 1

Jonathan Fassberg · CIK 0001750985 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,600

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on October 8, 2018 and vests 15% on October 8, 2019 and 15% on October 8, 2020, with the remainder vesting quarterly (commencing with the first fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-18-029912 · form4.xml · derivative · entry 1

Blome James · CIK 0001753563 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2028-10-08

F1 · derivative.exercise_date: The Stock Option was granted on October 8, 2018 and vests 15% on October 8, 2019 and 15% on October 8, 2020, with the remainder vesting quarterly (commencing with the first fiscal quarter of 2021) in equal installments over 42 months.

SEC source: 0001127602-18-029802 · form4.xml · nonDerivative · entry 1

Dumont Philippe · CIK 0001712186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,177

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017.

F2 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $14.08 to $14.19, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4

F3 · balance_after: Includes 16,660 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 2,940 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-029474 · form4.xml · nonDerivative · entry 1

Sahoo Manoj · CIK 0001712226 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,113

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on November 21, 2017.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.7019 to $14.96, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: Includes 63,700 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017, remain unvested and will vest quarterly in equal installments over the following 42 months.

SEC source: 0001127602-19-006028 · form5.xml · nonDerivative · entry 1

Blome James · CIK 0001753563 · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,464

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on September 17, 2018 and vested 25% on October 1, 2018, with 15% vesting on October 1, 2019, and the remainder vesting quarterly (commencing with the fourth fiscal quarter of 2019) in equal installments over 36 months.

SEC source: 0001127602-18-028219 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,338

Underlying: Common Stock · 4,666 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-028219 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-028219 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-027365 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,502

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-027365 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $15.79 to $16.62, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-027365 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-029914 · form4.xml · derivative · entry 2

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2028-08-21

F2 · derivative.exercise_date: The Stock Option was granted on August 21, 2018 and vests 33.3% on January 1, 2019, 33.3% on January 1, 2020, and 33.4% vesting on January 1, 2021.

SEC source: 0001127602-18-029914 · form4.xml · nonDerivative · entry 1

Ribeill Yves J · CIK 0001604049 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vests 33.3% on January 1, 2019, 33.3% on January 1, 2020, and 33.4% vesting on January 1, 2021.

SEC source: 0001127602-18-026014 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,004

Underlying: Common Stock · 4,666 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-026014 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.03 to $17.67, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-026014 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-025119 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,585

Underlying: Common Stock · 4,083 shares

Expires 2024-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-025119 · form4.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.98, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-025119 · form4.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,065

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-023818 · form4a.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,670

Underlying: Common Stock · 4,666 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).

SEC source: 0001127602-18-023818 · form4a.xml · nonDerivative · entry 2

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,982

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-023818 · form4a.xml · nonDerivative · entry 1

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,648

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 85,443 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.

SEC source: 0001127602-18-023816 · form4.xml · derivative · entry 3

Voytas Daniel F · CIK 0001712191 · Chief Science Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,670

Underlying: Common Stock · 4,666 shares

Expires 2026-04-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).